FDA clears Wellvii's finger-based blood pressure monitor for home use

Wellvii announced that its BP Go blood pressure monitoring device has received FDA clearance, a milestone the company says advances its work in remote patient monitoring and connected health.

BP Go uses a finger-based measurement method rather than the inflatable arm cuff used by most blood pressure devices on the market. Wellvii said the design is intended to simplify blood pressure checks and reduce the friction some patients experience with cuff-based devices, particularly in home and remote-care settings where consistent, repeat measurement matters for chronic condition management.

The company positioned the clearance as central to its broader strategy of extending connected health monitoring beyond the clinic and into patients' homes — an approach that aligns with the wider push toward remote patient monitoring as a tool for managing hypertension and other chronic conditions between office visits.

"This FDA clearance is a transformational milestone for Wellvii and BP Go," Mark Khachaturian, PhD, CEO, said in the announcement. "It brings us one step closer to making simple, accurate, and connected blood pressure monitoring available to millions of patients worldwide."

Wellvii did not disclose a commercial launch timeline, pricing, or specific health system or payer partnerships tied to the clearance. The company said BP Go is designed for both home use by individual patients and integration into remote-care programs run by providers.

The broader shift toward cuffless blood pressure monitoring

Wellvii's clearance is part of a wider trend in remote patient monitoring: device makers are increasingly pursuing cuffless and optical measurement methods — using the finger, wrist, or other sensor placements — as an alternative to the traditional inflatable arm cuff that has defined home blood pressure monitoring for decades.

The appeal for physicians and RPM program operators is largely about compliance. Traditional cuffs require correct positioning, a stable seated posture and several minutes of measurement time, all of which can suppress how often patients actually take and transmit readings. A device that trades the cuff for a faster, simpler input — a finger placement, a brief wearable scan — is intended to lower that barrier and increase the frequency of readings clinicians receive, which matters for hypertension management under value-based and RPM billing models that depend on regular, transmitted data.

That said, cuffless technologies face a higher clinical bar than incremental cuff improvements. Blood pressure accuracy standards from bodies such as the Association for the Advancement of Medical Instrumentation and the FDA's own guidance for novel BP measurement technology have made clearance for non-cuff devices a more involved process than for conventional oscillometric monitors, since alternative sensing methods must demonstrate they perform comparably across a range of patients, skin tones and vascular conditions. Regulators have also been more cautious about "cuffless" marketing claims broadly, given a history of consumer wearables offering blood pressure estimates without matching clinical-grade accuracy.

For practices building or expanding RPM programs, the practical questions tend to be less about the underlying sensor technology and more about reimbursement fit, EHR data integration and patient adherence over time — factors that determine whether a device that measures well in a validation study also performs well once it's in a patient's home for months at a stretch. As more entrants pursue FDA clearance for non-cuff blood pressure devices, physicians evaluating them for their own programs will likely look for published accuracy data alongside the clearance itself, along with clarity on how readings integrate with existing chronic care management workflows.